Generate Biomedicines (NASDAQ:GENB) Trading 4.9% Higher – Time to Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price rose 4.9% during mid-day trading on Tuesday . The company traded as high as $16.35 and last traded at $16.4660. 57,607 shares were traded during trading, a decline of 91% from the average daily volume of 657,916 shares. The stock had previously closed at $15.69.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. HC Wainwright lifted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Weiss Ratings initiated coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They issued a “sell (d)” rating on the stock. Finally, Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Price Performance

The company has a market cap of $2.08 billion and a PE ratio of -10.17. The stock’s fifty day simple moving average is $14.69.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. Equities analysts expect that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Generate Biomedicines

A hedge fund recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp bought a new stake in Generate Biomedicines Inc (NASDAQ:GENB) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 57,326 shares of the company’s stock, valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.